NCT00626418View on ClinicalTrials.gov

The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2008

Conditions
Restless Legs Syndrome
Interventions
DRUG

Aplindore

Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights

DRUG

Placebo

Placebo tablets

Trial Locations (5)

10019

Clinilabs, Inc., New York

30342

Sleep Disorders Center of Georgia, Atlanta

33009

MD Clinical, Hallandale

41017

Community Research, Crestview Hills

73112

Lynn Health Science Institute, Oklahoma City

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY